Pensionfund Sabic Takes $1.85 Million Position in Bristol Myers Squibb Company $BMY

Pensionfund Sabic purchased a new position in shares of Bristol Myers Squibb Company (NYSE:BMY) in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 34,200 shares of the biopharmaceutical company’s stock, valued at approximately $1,845,000.

Other institutional investors have also made changes to their positions in the company. Darwin Wealth Management LLC bought a new position in Bristol Myers Squibb in the second quarter valued at $25,000. Harbor Capital Advisors Inc. boosted its stake in shares of Bristol Myers Squibb by 107.2% during the 3rd quarter. Harbor Capital Advisors Inc. now owns 605 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 313 shares during the last quarter. KERR FINANCIAL PLANNING Corp bought a new position in shares of Bristol Myers Squibb in the 3rd quarter valued at about $35,000. JPL Wealth Management LLC acquired a new stake in shares of Bristol Myers Squibb in the third quarter valued at about $36,000. Finally, Total Investment Management Inc. bought a new stake in Bristol Myers Squibb during the second quarter worth about $38,000. Institutional investors own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Royal Bank Of Canada started coverage on Bristol Myers Squibb in a research report on Tuesday, February 24th. They set a “sector perform” rating and a $60.00 price target for the company. Piper Sandler reiterated an “overweight” rating and set a $75.00 price objective (up from $66.00) on shares of Bristol Myers Squibb in a research note on Monday, February 23rd. Weiss Ratings reissued a “hold (c)” rating on shares of Bristol Myers Squibb in a report on Monday. Wells Fargo & Company reissued an “outperform” rating and issued a $60.00 target price (up from $55.00) on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Finally, Citigroup upped their price target on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the stock a “neutral” rating in a research report on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Bristol Myers Squibb presently has an average rating of “Hold” and a consensus price target of $61.41.

Bristol Myers Squibb Stock Up 0.6%

BMY opened at $57.34 on Wednesday. The stock has a fifty day moving average of $58.66 and a 200-day moving average of $52.01. The company has a market capitalization of $116.77 billion, a P/E ratio of 16.62, a P/E/G ratio of 0.16 and a beta of 0.26. Bristol Myers Squibb Company has a fifty-two week low of $42.52 and a fifty-two week high of $62.89. The company has a debt-to-equity ratio of 2.32, a quick ratio of 1.14 and a current ratio of 1.26.

Bristol Myers Squibb (NYSE:BMY) last released its quarterly earnings results on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing analysts’ consensus estimates of $1.65 by ($0.39). Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The business had revenue of $12.50 billion for the quarter, compared to the consensus estimate of $12.24 billion. During the same period in the prior year, the business posted $1.67 earnings per share. Bristol Myers Squibb’s revenue was up 1.3% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. On average, equities analysts expect that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be issued a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.4%. Bristol Myers Squibb’s dividend payout ratio (DPR) is currently 73.04%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: FDA approves an expanded U.S. and EU label for Opdivo in classical Hodgkin lymphoma — this broadens an established immunotherapy’s addressable market and supports near-term revenue upside from higher utilization. FDA Approves BMY’s Opdivo Label Expansion in Classical Hodgkin Lymphoma Zacks: FDA Approves Opdivo Label Expansion
• Positive Sentiment: New Camzyos (mavacamten) data presented at ACC.26 reinforces BMS’s leadership in obstructive hypertrophic cardiomyopathy (oHCM) and supports the drug’s commercial trajectory. Positive clinical readouts can drive longer-term uptake and market confidence. Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos Data
• Positive Sentiment: insitro expanded its collaboration with BMS to nominate new ALS targets — a pipeline-boosting partnership that increases external R&D productivity and optionality in neurodegeneration. Successful programs could add medium/long-term value. insitro and Bristol Myers Squibb Collaboration Expanded
• Positive Sentiment: Multiple dividend-focused writeups highlight BMY’s 4%+ yield and dividend growth track record, which supports investor demand from income-focused funds and individual investors. Positive coverage can sustain or increase buy-side interest. Bristol-Myers Squibb: Dividend/Portfolio Renewal Thesis Remains Promising Should You Buy Bristol Myers Squibb Stock for Its 4.4%-Yielding Dividend?
• Neutral Sentiment: CEO Dr. Christopher Boerner was appointed to Colgate‑Palmolive’s board — a corporate governance/leadership note that is generally neutral for BMY but underscores executive credibility. Colgate-Palmolive Taps Healthcare And Regional Marketing Expertise For Growth
• Neutral Sentiment: Coverage of Anktiva and other industry competitors is visible in the newsflow — useful context on competitive dynamics but not an immediate BMY-specific catalyst. Can Anktiva’s Label Expansion Unlock the Next Growth Phase for IBRX?

Bristol Myers Squibb Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.